胰腺癌中的吉西他滨耐药性：找出关键因素。 - Suppr

Suppr

超能文献

Gemcitabine resistance in pancreatic cancer: picking the key players.

作者信息

Kim Michael P, Gallick Gary E

出版信息

Clin Cancer Res. 2008 Mar 1;14(5):1284-5. doi: 10.1158/1078-0432.CCR-07-2247.

DOI:10.1158/1078-0432.CCR-07-2247

PMID:18316544

Abstract

摘要

相似文献

Gemcitabine resistance in pancreatic cancer: picking the key players.胰腺癌中的吉西他滨耐药性：找出关键因素。

Clin Cancer Res. 2008 Mar 1;14(5):1284-5. doi: 10.1158/1078-0432.CCR-07-2247.

ASO Author Reflections: Regulation of Chemoresistance in Pancreatic Ductal Adenocarcinoma by Scavenger Receptor CD36.ASO作者反思：清道夫受体CD36对胰腺导管腺癌化疗耐药性的调控

Ann Surg Oncol. 2020 Feb;27(2):620-621. doi: 10.1245/s10434-019-08022-2. Epub 2019 Oct 28.

Lentivirus-mediated RNA interference of HMGA1 promotes chemosensitivity to gemcitabine in pancreatic adenocarcinoma.慢病毒介导的HMGA1基因RNA干扰增强胰腺腺癌对吉西他滨的化疗敏感性。

J Gastrointest Surg. 2006 Nov;10(9):1254-62; discussion 1263. doi: 10.1016/j.gassur.2006.06.011.

Annexin II overexpression predicts rapid recurrence after surgery in pancreatic cancer patients undergoing gemcitabine-adjuvant chemotherapy.膜联蛋白II过表达预示着接受吉西他滨辅助化疗的胰腺癌患者术后快速复发。

Ann Surg Oncol. 2008 Nov;15(11):3157-68. doi: 10.1245/s10434-008-0061-5. Epub 2008 Aug 20.

HMGA-targeted phosphorothioate DNA aptamers increase sensitivity to gemcitabine chemotherapy in human pancreatic cancer cell lines.HMGA 靶向硫代磷酸化 DNA 适体可提高人胰腺癌细胞系对吉西他滨化疗的敏感性。

Cancer Lett. 2012 Feb 1;315(1):18-27. doi: 10.1016/j.canlet.2011.10.005. Epub 2011 Oct 10.

Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity.CO-101 与吉西他滨治疗转移性胰腺导管腺癌的随机、多中心 II 期研究：包括对 hENT1 在吉西他滨或 CO-101 敏感性中作用的前瞻性评估。

J Clin Oncol. 2013 Dec 10;31(35):4453-61. doi: 10.1200/JCO.2013.51.0826. Epub 2013 Nov 12.

Cancer. Breaching the cancer fortress.癌症。突破癌症堡垒。

Science. 2009 Jun 12;324(5933):1400-1. doi: 10.1126/science.1175940.

[The inhibition of the Sonic Hedgehog (SHh) pathway improves the effects of chemotherapy in a model of ductal carcinoma of the pancreas in mice].[抑制音猬因子（SHh）信号通路可改善小鼠胰腺导管癌模型中的化疗效果]

Bull Cancer. 2009 Sep;96(9):829.

Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine.代谢组学预测接受吉西他滨治疗的胰腺导管腺癌患者的治疗结果。

Cancer Chemother Pharmacol. 2018 Feb;81(2):277-289. doi: 10.1007/s00280-017-3475-6. Epub 2017 Dec 1.

HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma.HMGA1是胰腺腺癌对吉西他滨化疗耐药的分子决定因素。

Clin Cancer Res. 2008 Mar 1;14(5):1470-7. doi: 10.1158/1078-0432.CCR-07-1450.

引用本文的文献

The Mechanism and Latest Progress of m6A Methylation in the Progression of Pancreatic Cancer.m6A甲基化在胰腺癌进展中的机制及最新研究进展

Int J Biol Sci. 2025 Jan 13;21(3):1187-1201. doi: 10.7150/ijbs.104407. eCollection 2025.

Identification of Metabolic Characteristic-Pancreatic Ductal Adenocarcinoma Associations Using Mendelian Randomization and Metabolomics.利用孟德尔随机化和代谢组学鉴定代谢特征与胰腺导管腺癌的关联

J Gastrointest Cancer. 2025 Jan 20;56(1):48. doi: 10.1007/s12029-025-01173-4.

Hsp90α promotes chemoresistance in pancreatic cancer by regulating Keap1-Nrf2 axis and inhibiting ferroptosis.热休克蛋白90α（Hsp90α）通过调节Keap1-Nrf2轴并抑制铁死亡来促进胰腺癌的化学抗性。

Acta Biochim Biophys Sin (Shanghai). 2024 Aug 22;57(2):295-309. doi: 10.3724/abbs.2024138.

N6-methyladenosine modified TGFB2 triggers lipid metabolism reprogramming to confer pancreatic ductal adenocarcinoma gemcitabine resistance.N6-甲基腺苷修饰的 TGFB2 触发脂质代谢重编程，赋予胰腺导管腺癌吉西他滨耐药性。

Oncogene. 2024 Jul;43(31):2405-2420. doi: 10.1038/s41388-024-03092-3. Epub 2024 Jun 24.

Single-Cell RNA Sequencing Analysis Reveals Metabolic Changes in Epithelial Glycosphingolipids and Establishes a Prognostic Risk Model for Pancreatic Cancer.单细胞RNA测序分析揭示上皮糖鞘脂的代谢变化并建立胰腺癌预后风险模型。

Diagnostics (Basel). 2024 May 24;14(11):1094. doi: 10.3390/diagnostics14111094.

PRMT1 promotes pancreatic cancer development and resistance to chemotherapy.PRMT1 促进胰腺癌的发展和化疗耐药性。

Cell Rep Med. 2024 Mar 19;5(3):101461. doi: 10.1016/j.xcrm.2024.101461. Epub 2024 Mar 8.

SMAD4 endows TGF-β1-induced highly invasive tumor cells with ferroptosis vulnerability in pancreatic cancer.SMAD4使TGF-β1诱导的高侵袭性肿瘤细胞在胰腺癌中具有铁死亡易感性。

Acta Pharmacol Sin. 2024 Apr;45(4):844-856. doi: 10.1038/s41401-023-01199-z. Epub 2023 Dec 6.

Prognostic value of RRM1 and its effect on chemoresistance in pancreatic cancer.RRM1 对胰腺癌的预后价值及其对化疗耐药性的影响。

Cancer Chemother Pharmacol. 2024 Mar;93(3):237-251. doi: 10.1007/s00280-023-04616-6. Epub 2023 Dec 1.

FTO-mediated LINC01134 stabilization to promote chemoresistance through miR-140-3p/WNT5A/WNT pathway in PDAC.FTO 通过 LINC01134 稳定促进胰腺导管腺癌的化疗耐药性，通过 miR-140-3p/WNT5A/WNT 通路。

Cell Death Dis. 2023 Nov 1;14(11):713. doi: 10.1038/s41419-023-06244-7.

In vivo label-free optical signatures of chemotherapy response in human pancreatic ductal adenocarcinoma patient-derived xenografts.人胰腺导管腺癌患者来源异种移植体化疗反应的体内无标记光学特征。

Commun Biol. 2023 Sep 25;6(1):980. doi: 10.1038/s42003-023-05368-y.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验